PharmaMar Forms License Agreement For Aplidin

PharmaMar has entered into an exclusive license and commercialization agreement with the pharmaceutical company Specialised Therapeutics Australia Pty (STA) to market and distribute the drug candidate Aplidin (plitidepsin) in Australia and New Zealand. PharmaMar will receive an upfront payment, royalties as well as additional remunerations for regulatory and sales milestones achieved by Aplidin. PharmaMar will retain exclusive production rights and will supply the finished product to STA for commercial use in Australia and New Zealand.

Aplidin is PharmaMar’s second anticancer drug candidate obtained from a marine organism and is currently under development for the treatment of multiple myeloma and a type of T cell lymphoma. The company announced in June that patient recruitment of the international pivotal Phase III trial (Admyre) for Aplidin (plitidepsin) in refractory/relapsed multiple myeloma was successfully completed.

“Our commitment to bringing innovative therapies to all patients continues, and this collaboration with a strong pharmaceutical group in Australia and New Zealand is crucial for the role of the anticancer drug plitidepsin in these two important territories,” said José María Fdez. Sousa-Faro, chairman, PharmaMar.